Lorlatinib Tablet shortage
To Be Discontinued 1 presentations · 1 manufacturers · first FDA posting 2026-06-15 · last update 2026-06-15
Manufacturers: Pfizer Inc.
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03) | Pfizer Inc. | To Be Discontinued | — | Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue to be manufactured; Discontinuation of the manufacture of this presentation | Posted 06/15/2026 Updated 06/15/2026 Discontinued 06/15/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)